Despite the lack of survival benefits compared to chemotherapy, pembrolizumab achieved better clinical benefit in the CPS ≥10 cohort than in the CPS ≥1 subgroup, suggesting that increased PD-L1 expression levels may improve OS for patients with GC. Here, CD274 is linked to gastric cancer.